

DR. LOUIS W. SULLIVAN, SECRETARY OF DEPT. OF HEALTH AND HUMAN SERVICES, NAMED PRESIDENT OF MOREHOUSE SCHOOL OF MEDICINE

Atlanta, GA— Dr. Louis W. Sullivan, Secretary of the Department of Health and Human Services, has been named President of the Morehouse School of Medicine.

In making the announcement, James B. Hayes, Chairman of the Morehouse Board of Trustees, and Publisher of FORTUNE magazine said: "On behalf of the Board of Trustees, the faculty, and students of Morehouse, we are delighted that our friend, Dr. Sullivan, will be returning as President to the school he founded in 1975. Dr. Sullivan served our country with great distinction as Secretary of HHS, developing a program for reform of the nation's health care system to provide all

Americans with access to affordable health care. We are very fortunate that Dr. Sullivan will lead the Morehouse School of Medicine in its unique mission to train African-American doctors dedicated to providing the highest quality health care to our nation's underserved in rural areas and inner cities in Georgia and nationwide. We know Dr. Sullivan will also guide the Morehouse School of Medicine's efforts to enhance its commitments to the communities it serves.

"We appreciate the excellent job Dr. Nelson McGhee did as interim president during the transition period, and we are very pleased that he will continue as a senior member of the Morehouse

HEALTH

staff, working closely with Dr. Sullivan."

Dr. Sullivan graduated magna cum laude from Morehouse College in 1954. Among his numerous awards and honorary degrees, Dr. Sullivan received the Benny Award from Morehouse for Outstanding Achievement in 1989.


Dr. Sullivan said: "I am very proud and deeply gratified that the Morehouse Board of Trustees has asked me to head our nation's first predominantly African-American medical education institution

established in this century. As our nation strives to offer adequate health care to its most vulnerable citizens, the Morehouse School of Medicine will educate and train students to provide more accessible humane health care for America's 35 million economically disadvantaged citizens. The Morehouse School of Medicine is more than a medical education program; it's a partnership between the trustees, faculty, and students to serve those communities most in need of medical care. It is a proud tradition and

one on which we will build."

The Morehouse School of Medicine seeks to educate physicians of conscience who will graduate from medical school and are uniquely sensitive to the health-care needs of the underserved and the poor. It attracts students who come from those communities. Students gain their medical education at Morehouse and then return to those communities to practice.

The Morehouse School of Medicine began as a two-year institution, with its students transferring to other institutions to



DR. LOUIS SULLIVAN

complete their education. Morehouse is now an independent, accredited four-year medical school, and in 1985 graduated its first full four-year class of MDs.

CCSN HEALTH INFO GRADS SCORE HIGH ON ACCREDITATION EXAMS


Four graduates of the Community College of Southern Nevada's Health Information Technology program recently scored in the 90th percentile on the national health information accreditation examination given by the American Health Information Management Association. Each graduate received the distinction of Accredited Records Technician.

The graduates were: Jeanne Broughton, ART, Health Information Manager of the Heart Institute of Nevada; Sheri Lagocki, ART, Health Information Manager, University Medical Center; Peggy Perkins, ART, Health Information Manager, Community Health Center of Southern Nevada and Patricia Weaver, ART, who is working in the health field in Phoenix.

ONE AWESOME SALE!

Fletcher Jones Chevrolet/Geo

BANKRUPTCY? POOR CREDIT? REPOSESSION?
See **JIM WEAVER** to help you find that New or Used Vehicle **TODAY!**



Jim Weaver

OVER 300 USED VEHICLES TO CHOOSE FROM!



'86 Chevy Cavalier #6352 was \$4999 **\$2499**



'88 Chevy Corsica #5983 was \$6999 **\$3499**



'88 Chevy Cavalier Z-24 #4729 loaded! was \$7999 **\$4499**



'89 Chevy Corsica #8188 was \$7999 **\$4499**



'90 Geo Storm #5881 was \$7499 **\$4499**



'89 Chevy Celebrity #8671 was \$7999 **\$4999**



'89 Chevy Beretta V6 #4504 was \$7999 **\$4999**



'90 Chevy Lumina #4473 was \$9999 **\$5999**



'88 Nissan Truck #4085 was \$6999 **\$3499**



'90 Toyota Truck #5839 was \$7999 **\$5499**



'87 GMC 3/4 T 4x4 #4368 was \$8999 **\$5999**



'88 S-10 Blazer #5394 was \$9999 **\$6999**



'89 GMC 1500 Stepside #8068 was \$10,999 **\$6999**



'88 Chevy 3/4 Ton #8314 was \$10,499 **\$7499**



'89 Chevy 3/4T 4x4 #8767 was \$12,999 **\$8999**



'89 GMC Suburban-Silverado #9066 was \$14,999 **\$12,999**

Mon-Saturday 8am to 10pm Se Habla Espanol

All vehicles subject to prior sale. **One Of The Worlds' Largest Automobile Dealers!**



444 SOUTH DECATUR BLVD. AT ALTA • 870-9444 or 1-800-CHEVYLV

NEWS OF HEALTH


FACTS FROM THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

AIDS Medication Recommendation

Low-dose oral interferon alpha in its various forms, including Kemron, are not recommended at this time for treatment of persons with HIV infection, according to a statement released by the AIDS Research Advisory Committee to the National Institute of Allergy and Infectious Diseases (NIAID). The committee statement concludes that several research studies—both ongoing and completed—do not support an earlier report that Kemron is an effective therapy.

In the statement, the committee also "strongly encourages HIV-infected patients to seek treatment with therapies whose benefits have been established in well-designed, controlled clinical trials," recommends that NIAID "encourage the completion and analysis of ongoing studies" of low-dose interferon alpha, and provide an updated report on ongoing research within a year.

U.S. Department of Health and Human Services (HHS) Secretary Louis W. Sullivan, M.D., said, "This report is extremely important because it provides state-of-the-science information on a controversial treatment—Kemron and other forms of low-dose



HIV-infected patients should seek treatment with therapies whose efficacy have been established in clinical trials, a recent research report concludes.

interferon alpha. These recommendations are vital to patients with HIV infection who want to make informed medical decisions, along with their physicians, about their treatment options."

The advisory committee, composed of non-federal medical professionals, researchers and persons with HIV infection, was mandated by Congress to advise the NIAID on treatment research and dissemination of the results of that research to the patient and professional communities. NIAID is the lead institute at the National Institutes of Health responsible for conducting, supporting and coordinating many aspects of federally sponsored research on HIV infection and AIDS.